Plain-English translation of NCT06581081 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing S1904, a type of immunotherapy that uses your own immune cells (CAR-T cells) to fight a difficult form of blood cancer called B-cell acute lymphoblastic leukemia. The main question is whether patients benefit more from receiving a stem cell transplant after the medication works, or whether the medication alone is sufficient for long-term survival.
While this type of CAR-T therapy has shown promising initial results, many patients relapse after treatment. Researchers want to know if adding a stem cell transplant afterward can prevent relapse and help patients stay cancer-free longer.
You likely qualify if…
You likely don't qualify if…
You would first receive S1904 CAR-T cell therapy as an infusion. Over the next 12 weeks, your doctors will monitor how well it works by checking your bone marrow and looking for minimal residual disease. If the treatment is successful, you'll be randomly assigned to either receive a stem cell transplant afterward or continue with follow-up care alone. You'll have regular check-ups and blood tests throughout the study to track your health and how long the treatment keeps working.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China